Spyre Therapeutics, Inc. (NASDAQ: SYRE) approved equity inducement awards for one non-executive employee to secure their employment with the clinical-stage biotechnology company.

The Compensation Committee of the Board of Directors authorized the grants on September 1, 2026, under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan. The awards comply with Nasdaq Listing Rule 5635(c)(4).

Award Structure

The package includes stock options and restricted stock units (RSUs) with specific vesting schedules tied to continuous service.

The exercise price of $88.50 reflects the closing price per share of Spyre’s common stock on Nasdaq as reported on September 1, 2026.

Vesting Schedule

Stock options vest in two phases:

• One-fourth (1/4th) of shares vest on the first anniversary of the employee’s start date.
• One-forty-eighth (1/48th) of shares vest monthly thereafter.

RSUs vest in four equal installments of one-fourth (1/4th) each. These payments occur on February 15, May 15, August 15, or November 15, starting from the first applicable date after the employee’s start date.

Company Profile

Spyre Therapeutics develops next-generation therapies for immunology. Its pipeline features investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F, alongside rational combination programs.

Spyre Therapeutics Inc (NASDAQ: SYRE) reported Phase 2 SKYWAY rheumatoid arthritis sub-study results for SPY072. The drug achieved statistical significance on select endpoints but missed the company's internal threshold to prioritize it as a monotherapy in RA. Shares fell 12.33% to $94.12.

The SKYWAY-RA sub-study is a randomised, placebo-controlled trial evaluating two doses of SPY072 in patients with moderate to severely active RA who had an inadequate response to conventional or advanced therapies. The primary endpoint was the change from baseline to Week 12 in Disease Activity Score in 28 joints, C-reactive protein (DAS28-CRP). The secondary endpoint was the proportion of patients achieving an ACR20 response at Week 12.

SKYWAY-RA efficacy results at Week 12

SPY072 Low Dose demonstrated a statistically significant benefit compared to placebo on the primary endpoint (change from baseline in DAS28-CRP) at Week 12. Nominally significant improvements versus placebo were observed on the secondary endpoint (ACR20) with High Dose and on the exploratory endpoint (ACR50) with Low Dose. Results were generally comparable between advanced-therapy-naive and advanced-therapy-experienced sub-groups. Both doses achieved target drug concentrations and provided complete and durable suppression of free TL1A through Week 12, indicating complete target engagement.

*p<0.05 for SPY072 versus placebo; **nominal p<0.05 for SPY072 versus placebo

Safety profile

SPY072 was well tolerated with a safety profile consistent with the TL1A class. Rates of adverse events were comparable between active (27%) and placebo (36%) arms and were generally mild or moderate. One serious treatment-emergent adverse event (TEAE) occurred on each arm, with none deemed drug-related. One death occurred in a participant receiving placebo. The most common TEAEs were infections and infestations, occurring in 14% of SPY072-treated participants and 15% of placebo-treated participants.

Management commentary

Cameron Turtle, DPhil, Chief Executive Officer at Spyre, stated that while the results do not lead the company to prioritise SPY072 as a monotherapy in RA, the favorable safety profile of TL1A inhibition alongside demonstrated efficacy across inflammatory bowel disease, hidradenitis suppurativa (HS), and RA provides increased conviction that Spyre's long-acting TL1A antibodies have potential in a range of autoimmune diseases and as combination components. Turtle also noted the initiation of the SKYLIGHT trial of SPY072 in combination with IL-17A/F in HS as the company's fourth investigational combination of validated mechanisms in autoimmune indications.

Pipeline readouts and next steps

Spyre outlined several expected topline readouts over the next 12-18 months across its immunology and inflammation pipeline.

Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F, as well as rational combination programs across autoimmune indications with high unmet need.